These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24029311)

  • 1. Re: Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
    Taneja SS
    J Urol; 2013 Oct; 190(4):1247. PubMed ID: 24029311
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Effect of age, tumor risk, and comorbidity on competing risks for survival in a u.s. Population-based cohort of men with prostate cancer.
    Penson DF
    J Urol; 2013 Nov; 190(5):1766-7. PubMed ID: 24120782
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of age, tumor risk, and comorbidity in a u.s. Population-based cohort of men with prostate cancer.
    Daskivich TJ; Litwin MS; Penson DF
    Ann Intern Med; 2013 Sep; 159(5):370. PubMed ID: 24026326
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of age, tumor risk, and comorbidity in a U.S. population-based cohort of men with prostate cancer.
    Froehner M; Koch R; Wirth MP
    Ann Intern Med; 2013 Sep; 159(5):370. PubMed ID: 24026325
    [No Abstract]   [Full Text] [Related]  

  • 5. Validation of an Age-adjusted Prostate Cancer-Specific Comorbidity Index.
    Froehner M; Koch R; Hübler M; Wirth MP
    Eur Urol; 2016 May; 69(5):764-6. PubMed ID: 26558839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Dash A; Greenfield S; Litwin MS
    Cancer; 2013 Oct; 119(19):3446-53. PubMed ID: 23861016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e209-15. PubMed ID: 23332383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
    Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.
    Rose BS; Chen MH; Wu J; Braccioforte MH; Moran BJ; Doseretz DE; Katin MJ; Ross RH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):778-784. PubMed ID: 27788950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011.
    Ording AG; Horváth-Puhó E; Lash TL; Ehrenstein V; Borre M; Vyberg M; Sørensen HT
    Acta Oncol; 2016 May; 55(5):611-8. PubMed ID: 26586474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
    Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which patients are at the highest risk of dying from competing causes ≤ 10 years after radical prostatectomy?
    Froehner M; Koch R; Litz RJ; Hakenberg OW; Wirth MP
    BJU Int; 2012 Jul; 110(2):206-10. PubMed ID: 22044591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age, Comorbidity, and the Risk of Prostate Cancer-Specific Mortality in Men With Biopsy Gleason Score 4+3: Implications on Patient Selection for Multiparametric MRI.
    Chandra RA; Chen MH; Zhang D; Loffredo M; D'Amico AV
    Clin Genitourin Cancer; 2015 Aug; 13(4):400-405. PubMed ID: 25862319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
    Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
    J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.
    Abdollah F; Schmitges J; Sun M; Jeldres C; Tian Z; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Int J Urol; 2012 Sep; 19(9):836-44. PubMed ID: 22574746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
    Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
    Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.